Articles tagged with Alzheimer Disease
John P. Cogswell, PhD, has been awarded the 2009 Alzheimer Award for his work on identifying microRNA changes in Alzheimer's disease brain and CSF, which yields putative biomarkers and insights into disease pathways. His research highlights the potential of microRNAs to aid clinical diagnosis.
Researchers at McGill University have identified a principal cause of Alzheimer's disease as the addition of a single phosphate to an amino acid in a key brain protein, tau. This breakthrough could lead to earlier diagnosis and potentially block the onset of the disease.
Researchers developed software to analyze brain images, identifying anatomic differences in three regions: hippocampus, entorhinal cortex, and supramarginal gyrus. This allows for accurate diagnosis of mild cognitive impairment and Alzheimer's disease with high accuracy.
A new risk index has been developed to predict the likelihood of developing Alzheimer's disease in people aged 65 and older. The 15-point scale identifies individuals at high risk, who are more likely to develop dementia within six years, and highlights surprising factors such as being underweight or having had coronary bypass surgery.
A new study suggests that early diagnosis and treatment of Alzheimer's disease can lead to significant cost savings and improved quality of life for patients and their families. The research estimates that earlier intervention could save billions of dollars in long-term care costs, while also providing positive social benefits.
A study found an association between low cognitive function and early-age related macular degeneration in older adults. The research suggests that the two conditions share similar complex pathogenesis and risk factors, including hypertension and vascular changes.
Research found that lower levels of alpha-beta peptide 1-42, tau, and phosphorylated tau 181 in cerebrospinal fluid are associated with a faster rate of cognitive decline among individuals with mild dementia. The study suggests that these biomarkers may be useful as entry criteria for clinical trials of disease-modifying therapies.
Researchers at Johns Hopkins University found a link between genetic variations in the neuroglobin gene and an increased risk of Alzheimer's disease. The study, published in Neurobiology of Aging, suggests that lower levels of neuroglobin may contribute to the development of Alzheimer's.
Researchers have found a connection between Sanfilippo syndrome and Alzheimer's disease, suggesting that new Alzheimer's drugs may provide therapy for the currently untreatable metabolic disorder. The study identified key proteins involved in the development of the disease, which could lead to effective treatment options.
Researchers at Beth Israel Deaconess Medical Center found that an episode of delirium rapidly accelerates cognitive decline and memory loss in Alzheimer's patients. The study, which analyzed data from 408 patients, revealed that the average decline on cognitive tests nearly doubled to 4.9 points per year following an episode of delirium.
Research published in Neurology shows that Alzheimer's patients who develop delirium experience rapid cognitive decline, with a rate three times faster than those without. The study suggests that preventing delirium may improve or delay memory problems.
Researchers have discovered protein aggregates in Sanfilippo syndrome type B that are similar to neurofibrillary tangles found in Alzheimer's disease. This finding suggests that new dementia treatments may also benefit patients with this rare genetic disorder, offering hope for improved treatment options.
A study published in the Journal of Cell Biology reveals that a mutated Alzheimer's-related protein called presenilin helps form and maintain nerve cell connections. The findings suggest that failing nerve transmission might be an early step in the disease's pathology.
Research reveals that people with emerging symptoms of Alzheimer's disease are less efficient at remembering high-value information. Clinicians may be able to train them to improve their memory by teaching strategic and selective encoding techniques.
Patients with very mild Alzheimer's disease can rely on implicit memory processes to support successful recognition of pictures, but struggle with word-based recall. Researchers hope to develop strategies that leverage implicit memory to improve learning and independence in patients with AD.
A study published in the Journal of Biological Chemistry reveals a novel protein called RANBP9, which when over-expressed leads to increased generation of amyloid-beta peptide. The researchers found that inhibiting RANBP9 may offer an alternative approach to therapy for Alzheimer's disease.
Researchers found that heavy NSAID use increased the risk of dementia by 66% among study participants. Despite initial findings suggesting a potential preventive effect, this new study indicates that NSAIDs only delay the onset of Alzheimer's disease. The study analyzed data from over 2,700 individuals and followed them for 12 years.
Researchers studied 2,736 participants over 12 years and found a 66% higher risk of dementia among heavy NSAID users. The study suggests that earlier findings suggesting NSAIDs prevent or delay Alzheimer's disease may have been due to younger age groups.
Researchers have discovered that proton pump inhibitors, commonly used to treat ulcers, have significant neuroprotective properties and can enhance the effects of ibuprofen when used together. This finding suggests a new treatment potential for Alzheimer's disease.
Researchers at Mayo Clinic have identified two chemicals that can increase the activity of a molecule called insulin-degrading enzyme (IDE), which helps break down proteins associated with Alzheimer's disease. The study suggests that activating IDE may offer a new therapeutic approach for treating and preventing the disease.
Scientists have discovered a compound that selectively targets the M1 receptor, implicated in diseases like AD and schizophrenia. This finding holds promise for developing an effective treatment with minimal side effects.
A team of scientists found that the p75 receptor molecule has a neuroprotective effect on the sympathetic nervous system in mice with Alzheimer's disease, challenging the prevailing view of its harmful role. The study suggests that p75 could be a target for new protocols to manage dementia and memory loss.
Researchers created a computational model to examine the role of certain proteins in familial Alzheimer's disease. The model found no link between amyloid beta plaques and tau tangles, but suggested that genetic mutations in proteins and GSK3 over-activation may contribute to the development of the disease.
Scientists successfully observed extensive nerve cell death in zebrafish with a severe form of Alzheimer's disease, enabling targeted search for drugs to stop dementia. This breakthrough allows for the testing of drugs on living organisms.
Researchers at UCL have identified a protein, SAP, as a potential therapeutic target for Alzheimer's disease. CPHPC, a new small molecule drug, removes SAP from the blood and brains of patients with Alzheimer's disease, showing promising results.
Researchers developed a test to quickly assess the effectiveness of Alzheimer's drugs in reducing amyloid beta production, which builds brain plaques. The test, SILK, was used to study LY450139, an Eli Lilly drug candidate, and showed a dose-dependent drop in A-beta production.
A recent study by Mount Sinai faculty suggests that a gene associated with type-2 diabetes decreases in Alzheimer's disease dementia cases. The research found that promoting PGC-1 content in brain cells attenuates hyperglycemic-mediated β-amyloid production, linking type-2 diabetic metabolic defects to increasing dementia.
A new study by scientists from Imperial College London and University of Oxford found that young adults with a genetic variant associated with Alzheimer's Disease exhibit changes in brain activity decades before any symptoms appear. The researchers used functional Magnetic Resonance Imaging (fMRI) to compare the brains of healthy young...
Researchers found that beta-amyloid protein generates nitric oxide, which attacks and damages mitochondria in neurons. This damage leads to synaptic injury and eventual nerve cell death, contributing to Alzheimer's disease progression.
Tiny, toxic protein particles severely disrupt neurotransmission and inhibit delivery of key proteins in Alzheimer's disease. The particles inhibit neurons from communicating with each other and with other target cells in the body.
Researchers at VIB have identified a molecule that can form the basis for a new therapy for Alzheimer's disease. By targeting the Aph1B γ-secretase complex, they hope to develop a medicine that can prevent the formation of amyloid plaques and stop the progression of the disease.
Researchers have discovered a mode of action for mysterious protein snarls found in Alzheimer's patients, suggesting a combination therapy approach. The findings identify two proteins, amyloid beta and tau tangles, that wreak havoc on the nervous system, causing neural function loss and memory decline.
A study published by the American Academy of Neurology found that brain cell loss in the hippocampus area precedes Alzheimer's disease. People with smaller hippocampal volumes and higher rates of shrinkage were two to four times more likely to develop dementia.
Researchers at Penn Medicine have developed a biomarker test that can confirm or rule out Alzheimer's disease by measuring cerebrospinal fluid concentrations of amyloid beta42 peptide and tau protein. The test accurately predicted the conversion from mild cognitive impairment to Alzheimer's disease in 81.8% of cases.
The ADNI has completed a high-density genome-wide analysis of over 800 participants, providing a unique opportunity for researchers to explore genetic factors related to Alzheimer's disease. The data will be shared with scientists worldwide for further analysis and gene discovery.
Researchers identified a new amyloid beta mutation that hinders Alzheimer's disease progression by preventing the formation of amyloid fibrils. This discovery offers potential therapeutic strategies for both sporadic and genetic forms of the disease.
A study by researchers at the University of Georgia found a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms. The team detected higher levels of these antibodies in patients' blood samples, which could lead to an early diagnosis and potentially improve patient quality of life.
New research published in The FASEB Journal suggests that slight dips in brain temperature can cause an increase in abnormal tau protein, which is associated with Alzheimer's disease. This finding highlights the need for caution when anesthetizing patients with Alzheimer's or at risk of developing the disease.
A study by Washington University School of Medicine found that individuals with lower levels of amyloid beta 42 in their cerebrospinal fluid had reduced whole brain volumes, suggesting early brain damage. The results suggest that Alzheimer's disease may harm the brain for years before symptoms appear.
Researchers found anesthesia induces phosphorylation of tau at sites related to Alzheimer's disease, increasing the risk for cognitive impairment. The study suggests that this mechanism links anesthesia to the risk of dementia and Alzheimer's disease.
Researchers at Columbia University Medical Center found that diabetes and high cholesterol are associated with faster cognitive decline in Alzheimer's patients. The study also suggests that controlling vascular conditions may help delay the progression of the disease.
Researchers at Yale University have identified a key role for cellular prion proteins in triggering the damage caused by amyloid-beta peptides in Alzheimer's patients. The study suggests that these proteins act as early targets for new therapies, offering promising hope for the treatment of this debilitating disease.
Scientists have discovered a new therapeutic target for Alzheimer's disease by uncovering the normal function of a brain protein. The discovery suggests that the disease stems from an imbalance in signaling between neurons, rather than toxicity from amyloid plaques.
A recent study found that individuals with parents diagnosed with Alzheimer's disease or dementia may experience low verbal and visual memory performances in middle age. The study suggests that the ApoEe4 gene plays a role in the transmission of Alzheimer's risk between generations.
Researchers at Boston University School of Medicine found that people whose parents have Alzheimer's disease or dementia perform worse on formal memory testing. The study also identified a strong genetic link between ApoE ε4 gene and the transmission of Alzheimer's disease risk between generations.
Researchers have discovered a drug that eases protein fusion, increasing learning capacity in mice with Alzheimer's disease. The treatment could offer new perspectives and alternatives to existing medications.
Researchers used Nuclear Magnetic Resonance Spectroscopy to study the tau protein's structure and interactions in neurons of Alzheimer's disease patients. The study found that abnormal phosphorylation of tau proteins disrupts their ability to bind to microtubules, leading to cell death and nerve damage.
Researchers used Nuclear Magnetic Resonance spectroscopy to analyze the structure of Tau, identifying structural properties and fast motions. This breakthrough provides insights into how phosphorylation alters binding to microtubules, leading to nerve cell damage.
Researchers at VIB confirm GPR3 protein's role in reducing amyloid plaques, a hallmark of Alzheimer's disease. The discovery paves the way for developing a new medicine to combat the disease and preserve brain cells.
Researchers identified a distinct brain atrophy pattern in patients with mild cognitive impairment (MCI) that predicts a higher risk of progressing to Alzheimer's disease. This pattern involves widespread cortical atrophy in areas beyond memory centers, indicating potential decline in cognitive function.
A study by American Academy of Neurology found that drivers with Alzheimer's disease commit 27% more safety errors than those without the condition. The research used off-road tests to measure thinking, movement, and visual skills, predicting driving safety.
A Mediterranean diet has been associated with a lower risk of mild cognitive impairment, as well as the transition from mild cognitive impairment to Alzheimer's disease. Participants who adhered to the highest scores for Mediterranean diet adherence had a 28% and 48% reduced risk, respectively.
Researchers found that BDNF treatment can prevent or reverse memory loss, cognitive impairment, and brain cell degeneration in animal models of Alzheimer's disease. The study suggests a potential novel approach to treating the disease by slowing its progression.
Researchers found that insulin shields neurons from toxic proteins in Alzheimer's disease, preserving memory-forming synapses. This discovery suggests a novel approach to treating the devastating disease by increasing insulin sensitivity in the brain.
A new study published in Neurology, a journal of the American Academy of Neurology, found that higher education levels do not slow down the rate of memory loss. Despite initial improvements in memory and thinking skills with more education, these advantages did not translate to slower decline over time.
A drug used to treat stroke patients may also improve learning and memory and reduce the risk of Alzheimer's disease, according to a new study. The active form of the parent drug Fasudil improved spatial learning and working memory in middle-aged rats.
Combining drugs that protect neurons with those targeting memory may be key to treating neurodegenerative diseases. Researchers at the Medical College of Georgia are exploring novel drug candidates that target specific disease targets and improve cognition, reaction time and attention.
UC Davis researchers are using MRI scans to identify distinct brain patterns that can detect the onset of Alzheimer's disease. The study aims to predict the rate of cognitive decline and provide a method for differentiating healthy aging from cognitive decline due to diseases like Alzheimer's.
A new study led by Michigan Medicine suggests that older Americans are supportive of family surrogate-based research, which can aid in the development of treatments for dementia. The survey found that most respondents believed society should allow family surrogate consent and would participate in such research if needed.
Researchers at Mayo Clinic have identified a gene variant on the X chromosome associated with an increased risk of developing late-onset Alzheimer's disease. Women who inherited two copies of the PCDH11X variant were found to be at substantially greater risk, while men with one copy also showed a significant increase in risk.